"My slides from my presentation at the European Neurological Society Meeting in Prague. The analysis shows that alemtuzumab is more effective than interferon-beta-1a (Rebif) in rendering someone with active MS free of disease activity using clinical and MRI markers of disease activity."
CoI: Multiple